Literature DB >> 21255853

Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients.

Małgorzata Waluś-Miarka, Barbara Katra, Danuta Fedak, Danuta Czarnecka, Przemysław Miarka, Ewa Woźniakiewicz, Maciej Małecki, Barbara Idzior-Waluś.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21255853     DOI： 10.1016/j.ijcard.2010.12.094

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  4 in total

1.  Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.

Authors:  Muyesser Sayki Arslan; Esra Tutal; Mustafa Sahin; Melia Karakose; Bekir Ucan; Gulfer Ozturk; Erman Cakal; Zeynep Biyikli Gencturk; Mustafa Ozbek; Tuncay Delibasi
Journal:  Endocrine       Date:  2016-10-15       Impact factor: 3.633

2.  Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification.

Authors:  Cai-Mei Zheng; Kuo-Cheng Lu; Chia-Chao Wu; Yung-Ho Hsu; Yuh-Feng Lin
Journal:  Int J Nephrol       Date:  2011-05-25

3.  Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension.

Authors:  Robin Condliffe; Josephine A Pickworth; Kay Hopkinson; Sara J Walker; Abdul G Hameed; Jay Suntharaligam; Elaine Soon; Carmen Treacy; Joanna Pepke-Zaba; Sheila E Francis; David C Crossman; Christopher M H Newman; Charles A Elliot; Allison C Morton; Nicholas W Morrell; David G Kiely; Allan Lawrie
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

Review 4.  The alliance of mesenchymal stem cells, bone, and diabetes.

Authors:  Nicola Napoli; Rocky Strollo; Angela Paladini; Silvia I Briganti; Paolo Pozzilli; Sol Epstein
Journal:  Int J Endocrinol       Date:  2014-07-16       Impact factor: 3.257
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.